Drug Trial Radar · NCT05062889
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
477
Planned (sponsor's estimate)
Start
May 17, 2023
Primary completion
Oct 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Gruppo Oncologico del Nord-OvestAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Servier; Foundation Medicine; Seagen Inc.
- First posted
- Sep 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with Trifluridine/Tipiracil could increase the rate of cases with undetectable ct-DNA and therefore improve DFS in a population at high-risk of relapse. An additional target-driven cohort of HER2+ RAS wild-type colon cancer patients will be assessed for ct-DNA clearance after a tailored treatment with Trastuzumab and Tucatinib plus FOLFOX
Conditions
- Stage II Colon Cancer
- Stage III Colon Cancer
- HER2-positive Colon Cancer
- RAS Wild-type Colon Cancer
Interventions
5-Fluorouracil continuous infusion FOLFOXIRI scheduleDrug
3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
5-Fluorouracil bolus FOLFOX scheduleDrug
400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
5-Fluorouracil continuous infusion FOLFOX scheduleDrug
2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
Oxaliplatin FOLFOX and FOLFOXIRI scheduleDrug
85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Oxaliplatin CAPOX scheduleDrug
130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
L-LeucovorinDrug
200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
CapecitabineDrug
Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
IrinotecanDrug
165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
Trifluridine/TipiracilDrug
35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
TrastuzumabDrug
4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
TucatinibDrug
300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ct-DNA clearance rate after the end of the adjuvant treatment (ERASE-CRC part 1)Time frame: 6 months from the enrollment of the last patient in the adjuvant treatment
- ct-DNA clearance rate after the end of post-adjuvant treatment (ERASE-CRC part 2)Time frame: 6 months from the enrollment of the last patient in post-adjuvant treatment
- ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven)Time frame: 6 months from the enrollment of the last patient in the target-driven adjuvant treatment
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Ospedale San Donato di Arezzo
Arezzo, Italy
Spedali Civili di Brescia
Brescia, Italy
Fondazione POLIAMBULANZA ISTITUTO OSPEDALIERO
Brescia, Italy
AOU Cagliari PO Policlinico Universitario Duilio Casula Presidio Policlinico Universitario "Duilio Casula"
Cagliari, Italy
A.O.U. di Ferrara Arcispedale Sant'Anna
Ferrara, Italy
A.O.U Careggi
Florence, Italy
E.O. Ospedali Galliera di Genova
Genova, Italy
Ospedale Misericordia di Grosseto
Grosseto, Italy
Azienda USL Toscana Nord Ovest di Livorno
Livorno, Italy
Ospedale San Luca di Lucca
Lucca, Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, Italy
Fondazione IRCCS INT - Milano
Milan, Italy
Ospedale San Raffaele
Milan, Italy
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, Italy
Istituto Oncologico Veneto IOV - IRCCS
Padua, Italy
Azienda USL di Piacenza
Piacenza, Italy
Nuovo Ospedale di Prato
Prato, Italy
AUSL Romagna
Ravenna, Italy
Azienda USL IRCCS di Reggio Emilia (centro principale Reggio Emilia e centro satellite Guastalla).
Reggio Emilia, Italy
Policlinico Tor Vergata Roma
Roma, Italy
Istituto per la ricerca sui tumori Regina Elena
Roma, Italy
Policlinico Fondazione Agostino Gemelli
Roma, Italy
Ospedale Fatebenefratelli Isola Tiberina
Roma, Italy
Ospedale Campostaggia Poggiponsi
Siena, Italy
IRCCS di Candiolo
Torino, Italy
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Italy
Fondazione Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, Italy
Azienda Ospedaliera Cardinale Giovanni Panico
Tricase, Lecce, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.